FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年8月13日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 佔有關事件前的現有已發 | | 庫存股份變動 | 每股發行/出售價 (註4) ...

智通财经APP讯，药明康德(02359)发布公告，该公司于2025年8月13日斥资2799.04万元人民币回购29.2 万股A股，每股回购价格为91.91-98.83元人民币。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年8月13日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 佔有關事件前的現有已發 | | 庫存股份變動 | 每股發行/出售價 (註4) ...

Core Viewpoint - WuXi AppTec (603259) is expected to achieve approximately 20.64% year-on-year revenue growth, reaching about 20.799 billion yuan in the first half of 2025, with a net profit attributable to shareholders expected to increase by approximately 101.92% to about 8.561 billion yuan [1] Group 1: Company Performance - The company continues to focus on its unique "integrated, end-to-end" CRDMO (Contract Research, Development, and Manufacturing) business model, expanding new capabilities and production capacity while optimizing production processes and improving operational efficiency [1] - As of the end of 2024, WuXi AppTec has approximately 6,000 active clients, with about 5,500 in its ongoing business, and added around 1,000 new clients throughout the year [2] - The company's backlog for ongoing business reached 49.31 billion yuan, representing a year-on-year increase of 47.0% [2] Group 2: Industry Context - The performance of WuXi AppTec is closely linked to the development of the global pharmaceutical industry and investments in new drug research and development [1] - The global pharmaceutical market is expected to continue growing due to factors such as economic development, population growth, aging demographics, technological advancements, rising healthcare expenditures, and increasing public demand for healthy living [1]

Core Insights - WuXi AppTec (603259) reported a strong performance in the first half of 2025, with revenue reaching 20.799 billion yuan, a year-on-year increase of 20.64%, and net profit attributable to shareholders rising by 101.92% to 8.56 billion yuan [1][2] Group 1: Financial Performance - The company achieved a revenue of 20.41 billion yuan from continuing operations, with a year-on-year growth of 24.24% [1] - The TIDES business (oligonucleotides and peptides) saw significant growth, with revenue reaching 5.03 billion yuan, a year-on-year increase of 141.6% [2] - The company completed cash dividends totaling 3.84 billion yuan in the first half of 2025, including 2.83 billion yuan for the 2024 fiscal year and a special dividend of 1.01 billion yuan for 2025 [2] Group 2: Business Operations and Growth - The company reported a backlog of orders for continuing operations amounting to 56.69 billion yuan, a year-on-year increase of 37.2% [1] - Revenue from U.S. clients was 14.03 billion yuan, reflecting a year-on-year growth of 38.4%, while European clients contributed 2.33 billion yuan, growing by 9.2% [1] - The company is expanding its global footprint, with successful FDA inspections at its Changzhou and Taixing API bases and ongoing construction of its Middleton facility in the U.S. expected to be operational by the end of 2026 [3] Group 3: Future Outlook - The company raised its full-year revenue guidance, expecting a growth rate for continuing operations to be adjusted from 10%-15% to 13%-17% [3] - Overall revenue guidance was increased from 41.5 billion yuan - 43 billion yuan to 42.5 billion yuan - 43.5 billion yuan [3] - The CEO highlighted the unique advantages of the CRDMO business model and the commitment of the global team as key factors driving the company's strong growth momentum [3]

表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 1). | 購回股份(或其他證券)但沒有註銷 | 302,500 | 0.01 % | RMB | 66.14 | | --- | --- | --- | --- | --- | --- | | | 茲提述本公司於2025年3月17日刊發的公告，於2025年3月26日刊發的 | | | | | | | 通函，及於2025年4月29日刊發的投票結果公告。 | | | | | | | 於2025年6月26日，本公司實施2025年以集中競價交易方式回購本公司 | | | | | | | A股股份方案（"2025年第一次回購"），并回購302,500股A股股份。 | | | | | | | 變動日期 2025年6月26日 | | | | | | 2). | 購回股份(或其他證券)但沒有註銷 | 303,367 | | | | | | | | 0.01 % | RMB | 65.96 | | | 茲提述本公司於2025年3月17日 ...

药明康德（603259）(02359)发布公告，该公司于2025年8月12日斥资2799.23万元人民币回购30.79万股 股份，每股回购价格为90.13-91.6元人民币。 ...

格隆汇8月12日丨药明康德(02359.HK)发布公告，2025年8月12日耗资2799.23万元人民币回购30.79万股 A股，回购价格每股90.13-91.6元。 ...

智通财经APP讯，药明康德(02359)发布公告，该公司于2025年8月12日斥资2799.23万元人民币回购30.79 万股股份，每股回购价格为90.13-91.6元人民币。 ...

表格類別： 股票 狀態： 新提交 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年8月12日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 ...